Researchers Receive $4.2M Grant to Improve PrEP Access and Prevent New HIV Infections

Bronx county has the country’s fifth-highest rate of HIV diagnosis—but the lowest rate in New York State for use of HIV pre-exposure prophylaxis (PrEP), medications that are extremely effective in preventing HIV infection. Physician-researchers at Albert Einstein College of Medicine and Montefiore Health System have received a five-year, $4.2 million grant from the National Institutes of Health to compare two strategies for improving PrEP access and use in the Bronx.

PrEP Stigma Still High Among Men Who Have Sex With Men

Many male couples in the U.S. seem to be underestimating the effectiveness of HIV pre-exposure prophylaxis (PrEP) for HIV prevention, and educating partners together could improve the number of male couples who decide to adopt PrEP. These conclusions come from a study reported in the July/August issue of The Journal of the Association of Nurses in AIDS Care (JANAC), the official journal of the Association of Nurses in AIDS Care. JANAC is published in the Lippincott portfolio by Wolters Kluwer.

New Study Suggests Healthcare Provider Biases Can Impact a Patient’s Access to Preventative HIV Drug

A new study published today reveals systematic biases among primary and HIV care providers about people who inject drugs and how those biases may impact access to pre-exposure prophylaxis (PrEP), a preventive, prescription-based medication that significantly reduces the risk of HIV infection through sexual behavior and injection practices.

People at High Risk for HIV Know about Prevention Pill, But Use Remains Low

Cisgender sexual minority men and transgender women are aware of pre-exposure prophylaxis (PrEP), a daily pill for HIV-negative people to prevent HIV infection, but few are currently taking it, according to researchers at Rutgers.
The study, published in the journal AIDS and Behavior, surveyed 202 young sexual minority men and transgender women – two high-priority populations for HIV prevention – to better understand why some were more likely than others to be taking PrEP.

Study Finds Low Awareness of PrEP, the Highly Effective Medication that Protects Individuals from HIV

A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that just under 20 percent of HIV-uninfected patients visiting Baltimore sexual health clinics were aware of pre-exposure prophylaxis medication (PrEP), a daily regimen that decreases a person’s risk of contracting HIV from sex by more than 90 percent.

April 2021 Issue of AJPH highlights COVID-19 as it relates to unemployment and excess deaths in Florida, Medicaid expansion, and misinformation spread by crowdfunding campaigns

April 2021 highlights from AJPH Issue includes COVID-19-related articles around deaths linked to unemployment, higher than reported death toll in Florida and crowdfunding campaigns spreading misinformation

State Laws Key to HIV Prevention Efforts

HIV prevention remains a public health priority in the United States. Pre-exposure prophylaxis (PrEP) is a drug regimen recommended for individuals who have engaged in behaviors that place them at elevated risk for HIV. When used consistently, daily oral PrEP has been shown to reduce HIV transmission by 99 percent. However, despite increases in PrEP awareness and uptake over the past several years, data show that four of five people who could benefit from PrEP did not access the medication in 2018.

Twitter chat with HIV/AIDS experts from the Johns Hopkins School of Nursing, Nov. 26, to prepare for World AIDS Day

The Johns Hopkins School of Nursing @JHUNursing is hosting a Twitter Chat in advance of World AIDS Day featuring its practitioners, researchers, and experts in HIV care, prevention, and science. Tuesday, November 26, 4:00 pm, EST Join and ask questions…